Hims Launches Oral Wegovy Knockoff, But The FDA Could Prove To Be A Problem

Hims Stock Slides After Launching Oral Wegovy Knockoff; Novo, Lilly Tumble | Investor's Business DailySPECIAL REPORT: [Find The Online Broker That Best Fits Your Needs]---Hims & Hers Health (HIMS) launched a compounded version of Novo Nordisk's (NVO) already popular weight-loss pill on Thursday. But Hims stock reversed its early gains, while Novo and Eli Lilly (LLY) continued falling. The compounded pill will cost just $49 for the first month, roughly $100 less than what Novo Nordisk is charging for its ora ...